Lenaton Tablet 10 mg (Enalapril Maleate)

Adult dosage

1. Hypertension 1) Patients not receiving diuretics Adults: The initial dose is 5㎎ once daily as enalapril maleate, adjusted according to blood pressure. The maintenance dose is 10 ~ 40㎎ per day, administered in 1 ~ 2 divided doses. If the blood pressure-lowering effect decreases at the end of the dosing interval in patients receiving once-daily dosing, increase the dose or administer it twice daily. 2) Patients receiving diuretics Adults: Hypotension may occur when this medicine is first administered to patients recently treated for hypertension with a diuretic. Therefore, discontinue the diuretic, if possible, 2-3 days before starting this medicine. If hypertension is not controlled when this medicine is administered, the diuretic may be resumed. If the diuretic cannot be discontinued, administer this medicine orally at 2.5㎎ once daily. 3) Patients with renal impairment ① The usual dosage applies to patients with a creatinine clearance of 30㎖/min or higher (serum creatinine up to 3㎎/㎗). ② Patients with a creatinine clearance of 30㎖/min or lower (serum creatinine of 3㎎/㎗ or higher): The initial dose is 2.5㎎ once daily. The dose may be increased to a maximum of 40㎎ per day until blood pressure is controlled. ③ In patients not undergoing dialysis, determine the dose according to the blood pressure response. 2. Heart failure 1) This medicine is used as adjunctive therapy to diuretics and digitalis. 2) Initial dose Adults: Administer 2.5㎎ per dose, 1 ~ 2 times daily. After the first dose, observe the patient closely for at least 2 hours and until blood pressure is stable; reduce the diuretic dose, if possible, to prevent hypotension. If hypotension occurs after the first dose of this medicine, continue to adjust the dose carefully and manage the hypotension effectively. 3) Maintenance dose Adults: Administer 5 ~ 20㎎ per day in 2 divided doses; the dose may be increased to a maximum of 40㎎ per day. In controlled trials in which most patients received the maximum daily dose of 40㎎, effective results were obtained with once-daily dosing; however, twice-daily dosing has generally been used more often. In placebo-controlled trials involving patients with severe heart failure (NYHA class Ⅳ), in which reduced mortality was confirmed, most patients received 2.5 ~ 40㎎ per day in 2 divided doses. The dose may be adjusted according to the hemodynamic or clinical response. 4) Patients with heart failure accompanied by renal impairment or hyponatremia In patients with heart failure and hyponatremia (serum sodium concentration 130mEq/ℓ or lower) or serum creatinine of 1.6㎎/㎗ or higher, administer an initial dose of 2.5㎎ per day with close observation. If increasing the dose, administer 2.5 ~ 5㎎ per dose twice daily, or increase it further if necessary. Increase the dose only if excessive hypotension or significant deterioration in renal function has not occurred during the 4 days or longer after the initial dose. The dose may be increased to a maximum of 40㎎ per day.

This medication should not be taken by certain patients. For example, individuals who are allergic to this medication or have previously experienced an allergic reaction, patients undergoing hemodialysis, and individuals with a history of angioedema should not take this medication. It is also not recommended for patients with primary hyperaldosteronism, aortic stenosis, liver disease, kidney transplant recipients, women who are pregnant or breastfeeding, and children. Patients with reduced kidney function or renal artery hypertension, individuals with cerebrovascular disorders, patients with significant proteinuria, those with severe hypertension, individuals with serious electrolyte imbalances, immune disorders or collagen diseases, and elderly individuals should use this medication with extra caution. This medication may affect kidney function, so kidney function tests should be conducted before and during use. Additionally, blood pressure may drop suddenly when starting this medication, so it should be initiated at a low dose and the patient's condition should be closely monitored. During treatment, dizziness or lightheadedness may occur, so it is advisable to avoid driving or operating hazardous machinery. This medication may interact with other drugs, so caution should be taken when used in conjunction with potassium-sparing diuretics, lithium, non-steroidal anti-inflammatory drugs, other antihypertensives, immunosuppressants, alcohol, psychiatric medications, and hypoglycemic agents. Women who are pregnant or may become pregnant should not take this medication, and if breastfeeding, should either avoid it or cease breastfeeding. The safety in children has not been established, so it is advisable not to use it in pediatrics. Elderly patients should start at a low dose and use cautiously to prevent excessive blood pressure reduction that could lead to cerebrovascular issues. Patients receiving this medication who undergo venom desensitization treatment may need to be monitored carefully for serious allergic reactions. Finally, this medication should be stored out of reach of children, and transferring it to another container should be avoided to maintain its quality and safety.

• Increased BUN
• increased serum creatinine
• acute renal failure
• decreased hemoglobin
• decreased hematocrit
• decreased white blood cells
• decreased platelets
• increased eosinophils
• positive antinuclear antibody
• angioedema

This medication should be stored in a tightly sealed container to protect it from air and moisture exposure. This will help maintain the medication's effectiveness for a longer period.

Appearance

For domestic use: white round tablet, For export: yellowish round tablet

Package unit

For domestic use: 30 tablets/bottle